Novonesis A S (NVZMF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to the NOVESIS interim report for the first nine months of 2025 conference call. I'm Lorenzo, the chorus call operator. I would like to remind you that all participants will be in listen-only mode. The presentation will be followed by a Q&A session. You can register for questions at any time by pressing star and 1 on your telephone. For operator assistance, please press star and 0. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Tobias Cornelius Bjorklund. Please go ahead. Thank you, operator, and welcome everyone to the NovoNesis conference call for the first nine months of 2025. As mentioned, my name is Tobias Björklund. I'm heading up investor relations here at NovoNesis. In this call, our CEO, Esther Barchett, and our CFO, Reiner Lehmann, will review our performance for the first nine months of the year, as well as the outlook for 2025. Attending today's call, we also have Tina Fehrner, EVP of Planetary Health Biosolutions, Henrik-Jörg Nilsson, EVP of Human Health Biosolutions, Andrew Taylor, EVP of Food and Health Biosolutions, and Klaus-Krone Fuglsang, Chief Scientific Officer. The conference call will take about 45 minutes, including Q&A. Please change to the next slide. As usual, I would like to remind you that the information presented during the call is unaudited and that management may make forward-looking statements. These statements are based on current expectations and beliefs, and they involve risks and uncertainties that could cause actual results to differ materially from those described in any forward-looking statement. With that, I will now hand you over to our CEO, Esther. Esther, please. Thank you. Thank you, Tobias, and welcome, everyone. Thank you for...